# Revvity (RVTY) — Earnings

RVTY · NYSE · Stock

Canonical page: https://www.lighthorse.io/tickers/rvty/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2026 |
| Period end | Jul 5, 2026 |
| EPS actual | $1.41 |
| EPS estimate | $1.21 |
| EPS surprise | +16.16% |
| Revenue surprise | +1.14% |
| Revenue | $711.0M |
| Revenue estimate | $703.0M |
| Reported | Aug 4, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/31791/000003179126000027/revv-20260705.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/3821489a-d0d5-e708-1921-4da7374e514b.html) |

Revvity reported Q2 2026 results on August 4, 2026. Earnings per share came in at $1.41, ahead of the $1.21 estimate by 16.16%. Revenue was $711.0 million, above the $703.0 million consensus by 1.14%. Compared with Q2 2025, EPS rose about 19% from $1.18, while revenue slipped about 1% from $720.3 million.

The table has two distinct phases. Through Q3 2022, quarterly revenue ran between $1.0 billion and $1.4 billion and EPS between $1.51 and $2.56. From Q4 2022 onward, revenue has stayed between about $650 million and $772 million. Annual EPS fell from $7.94 in 2022 to $4.65 in 2023, then rose to $4.90 in 2024 and $5.07 in 2025. The first half of 2026 adds up to $2.45 per share, about 12% more than a year earlier. Q4 has been the strongest quarter of each recent year. Over the last 20 quarters, Revvity beat the EPS estimate 19 times. The only miss was Q3 2023, at 1.15% below.

Revvity reported its third quarter between October 27 and November 8 in each of the past five years. That points to late October or early November 2026 for the next report. It will show whether the year-over-year EPS gains continue.

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2026 | Aug 4, 2026 | $1.21 | $1.41 | 16.16% | $703.0M | $711.0M |
| Q1 2026 | May 5, 2026 | $1.02 | $1.04 | 2.24% | $704.2M | $711.1M |
| Q4 2025 | Feb 2, 2026 | $1.57 | $1.70 | 8.31% | $764.4M | $772.1M |
| Q3 2025 | Oct 27, 2025 | $1.14 | $1.18 | 3.42% | $699.4M | $698.9M |
| Q2 2025 | Jul 28, 2025 | $1.15 | $1.18 | 2.78% | $710.8M | $720.3M |
| Q1 2025 | Apr 28, 2025 | $0.95 | $1.01 | 6.46% | $661.0M | $665.0M |
| Q4 2024 | Jan 31, 2025 | $1.37 | $1.42 | 3.77% | $727.9M | $729.6M |
| Q3 2024 | Nov 4, 2024 | $1.13 | $1.28 | 13.65% | $679.7M | $684.3M |
| Q2 2024 | Jul 29, 2024 | $1.12 | $1.22 | 8.74% | $690.3M | $691.9M |
| Q1 2024 | Apr 29, 2024 | $0.94 | $0.98 | 3.98% | $647.2M | $650.1M |
| Q4 2023 | Feb 1, 2024 | $1.16 | $1.25 | 7.32% | $677.1M | $696.1M |
| Q3 2023 | Oct 30, 2023 | $1.19 | $1.18 | -1.15% | $695.4M | $670.9M |
| Q2 2023 | Aug 1, 2023 | $1.19 | $1.21 | 1.78% | $708.4M | $709.3M |
| Q1 2023 | May 11, 2023 | $1.00 | $1.01 | 1.14% | $678.9M | $675.1M |
| Q4 2022 | Feb 14, 2023 | $1.64 | $1.70 | 3.73% | $1.0B | $741.4M |
| Q3 2022 | Nov 8, 2022 | $1.44 | $1.51 | 4.85% | $1.0B | $1.0B |
| Q2 2022 | Aug 1, 2022 | $2.01 | $2.32 | 15.19% | $1.2B | $1.2B |
| Q1 2022 | May 3, 2022 | $2.12 | $2.41 | 13.95% | $1.2B | $1.3B |
| Q4 2021 | Feb 1, 2022 | $2.25 | $2.56 | 13.89% | $1.3B | $1.4B |
| Q3 2021 | Nov 2, 2021 | $1.74 | $2.31 | 32.75% | $1.0B | $1.2B |

## Frequently Asked Questions

### When did Revvity (RVTY) last report earnings?

Revvity last reported on Aug 4, 2026, covering fiscal Q2 2026.

### Did RVTY beat earnings estimates?

Yes. Revvity reported EPS of $1.41 for Q2 2026 against a $1.21 estimate — a 16.16% beat.

### How much revenue did RVTY report last quarter?

Revvity reported $711.0M in revenue for Q2 2026, against a consensus estimate of $703.0M.

## Similar Stocks

- [TMO](https://www.lighthorse.io/tickers/tmo) — Thermo Fisher Scientific Inc Common Stock
- [A](https://www.lighthorse.io/tickers/a) — Agilent Technologies, Inc. Common Stock
- [BRKR](https://www.lighthorse.io/tickers/brkr) — Bruker Corporation - Common Stock
- [WAT](https://www.lighthorse.io/tickers/wat) — Waters Corporation Common Stock
- [MTD](https://www.lighthorse.io/tickers/mtd) — Mettler-Toledo International, Inc. Common Stock
- [TECH](https://www.lighthorse.io/tickers/tech) — Bio-Techne Corp - Common Stock
- [IQV](https://www.lighthorse.io/tickers/iqv) — IQVIA Holdings, Inc. Common Stock
- [CRL](https://www.lighthorse.io/tickers/crl) — Charles River Laboratories International, Inc. Common Stock
- [BIO](https://www.lighthorse.io/tickers/bio) — Bio-Rad Laboratories, Inc. Class A Common Stock
- [DHR](https://www.lighthorse.io/tickers/dhr) — Danaher Corporation Common Stock

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).